Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients
space
 arrow  Summary for Patients (PDF)
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Sjölund, M.
space
  arrow  Engstrand, L.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

BRIEF COMMUNICATION

Long-Term Persistence of Resistant Enterococcus Species after Antibiotics To Eradicate Helicobacter pylori

right arrow Maria Sjölund, MSc; Karin Wreiber, MSc; Dan I. Andersson, PhD; Martin J. Blaser, MD; and Lars Engstrand, MD

16 September 2003 | Volume 139 Issue 6 | Pages 483-487

Background: Antibiotic treatment selects for resistance not only in the pathogen to which it is directed but also in the indigenous microflora.

Objective: To determine whether a widely used regimen (clarithromycin, metronidazole, and omeprazole) for Helicobacter pylori eradication affects resistance development in enterococci.

Design: Cohort study.

Setting: Endoscopy units at 3 community hospitals in Sweden.

Patients: 5 consecutive dyspeptic patients who were colonized with H. pylori, had endoscopy-confirmed duodenal ulcer, and received antibiotic treatment, and 5 consecutive controls with dyspepsia but no ulcer who did not receive treatment.

Measurements: Fecal samples were obtained from patients and controls before, immediately after, 1 year after, and 3 years after treatment. From each patient and sample, enterococci were isolated and analyzed for DNA fingerprint, clarithromycin susceptibility, and presence of the erm(B) gene.

Results: In treated patients, all enterococci isolated immediately after treatment showed high-level clarithromycin resistance due to erm(B). In 3 patients, resistant enterococci persisted for 1 to 3 years after treatment. No resistance developed among controls.

Conclusion: A common H. pylori treatment selects for highly resistant enterococci that can persist for at least 3 years without further selection.


Editors' Notes
space

Context

  • Antibiotics are selective killers. Regardless of the indication, they may leave behind resistant bacteria.

Contribution

  • In this study, fecal enterococci isolated from 5 dyspeptic patients treated with clarithromycin for ulcers associated with Helicobacter pylori infection were compared with enterococci from 5 dyspeptic patients without ulcers who did not receive antibiotics. All enterococci isolated immediately after treatment were highly resistant to clarithromycin; enterococci in untreated patients were clarithromycin sensitive. In 3 treated patients, resistant organisms persisted for 1 to 3 years.

Implications

  • Short-term clarithromycin treatment of H. pylori infection leaves behind indigenous bacteria resistant to that antibiotic.

–The Editors

 

Author and Article Information
space

From University Hospital Uppsala, Uppsala, and The Swedish Institute for Infectious Disease Control, Solna, Sweden; and New York University School of Medicine, New York, New York.

Acknowledgments: The authors thank Lena Zimmergren for coordinating the collection of samples and Lena Eriksson and Kristina Schönmeyr for excellent technical assistance.

Grant Support: By the AFA Health Research Foundation, Stockholm, Sweden, and by the National Institutes of Health (RO1GM63270).

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Lars Engstrand, MD, Department of Bacteriology, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden; e-mail, lars.engstrand{at}smi.ki.se.

Current Author Addresses: Ms. Sjölund: Department of Medical Sciences, Clinical Bacteriology, University Hospital Uppsala, Box 552, SE-751 22 Uppsala, Sweden.

Ms. Wreiber and Drs. Andersson and Engstrand: Department of Bacteriology, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.

Dr. Blaser: Departments of Medicine and Microbiology, New York University School of Medicine, New York, NY 10016.

Author Contributions: Conception and design: M. Sjölund, L. Engstrand.

Analysis and interpretation of the data: M. Sjölund, D.I. Andersson, M.J. Blaser, L. Engstrand.

Drafting of the article: M. Sjölund, D.I. Andersson, M.J. Blaser, L. Engstrand.

Critical revision of the article for important intellectual content: M. Sjölund, D.I. Andersson, M.J. Blaser, L. Engstrand.

Final approval of the article: M. Sjölund, K. Wreiber, D.I. Andersson, M.J. Blaser, L. Engstrand.

Provision of study materials or patients: K. Wreiber.

Obtaining of funding: L. Engstrand.

Administrative, technical, or logistic support: K. Wreiber, L. Engstrand.

Collection and assembly of data: K. Wreiber, L. Engstrand.


Related articles in Annals:

Articles
The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections
Brian J. McMahon, Thomas W. Hennessy, J. Michael Bensler, Dana L. Bruden, Alan J. Parkinson, Julie M. Morris, Alisa L. Reasonover, Debby A. Hurlburt, Michael G. Bruce, Frank Sacco, AND Jay C. Butler
Annals 2003 139: 463-469. [ABSTRACT][SUMMARY][Full Text]  

Editorials
Collateral Damage
Louis B. Rice
Annals 2003 139: 523-524. [Full Text]  

Summaries for Patients
Effects of Antibiotic Treatment for Helicobacter pylori on Normal Bowel Bacteria
Annals 2003 139: I-42. [Full Text]  



This article has been cited by other articles:


Home page
Therapeutic Advances in GastroenterologyHome page
Y.-C. Lee, J.-M. Liou, C.-Y. Wu, and J.-T. Lin
Review: Eradication of Helicobacter pylori to prevent gastroduodenal diseases: Hitting more than one bird with the same stone
Therapeutic Advances in Gastroenterology, September 1, 2008; 1(2): 111 - 120.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
F. Francois and M. J. Blaser
Improving Helicobacter pylori Eradication Regimens
Ann Intern Med, January 17, 2006; 144(2): 140 - 141.
[Full Text] [PDF]


Home page
EDUCATION AND PRACTICEHome page
D I Campbell and J E Thomas
Helicobacter pylori infection in paediatric practice
Arch. Dis. Child. Ed. Pract., August 1, 2005; 90(2): ep25 - ep30.
[Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
D. H. Mariam, Y. Mengistu, S. E. Hoffner, and D. I. Andersson
Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis
Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1289 - 1294.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
JournalScan
Gut, February 1, 2004; 53(2): 314 - 314.
[Full Text] [PDF]


Home page
Journal Watch DermatologyHome page
H. pylori Treatment Resistance
Journal Watch Dermatology, November 26, 2003; 2003(1126): 9 - 9.
[Full Text]


Home page
JWatch GeneralHome page
H. pylori Treatment Resistance
Journal Watch (General), October 14, 2003; 2003(1014): 4 - 4.
[Full Text]


Home page
ANN INTERN MEDHome page
L. B. Rice
Collateral Damage
Ann Intern Med, September 16, 2003; 139(6): 523 - 524.
[Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2003 by the American College of Physicians.